GHO-CAPITAL-PARTNERS-LLP
Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, today announces the sale of Caprion Biosciences (“Caprion”) to Arsenal Capital Partners, a leading specialized private equity firm that invests in middle-market healthcare and specialty industrials companies.
Caprion is a specialized laboratory service business serving pharma and biotech companies for their research and development activities throughout the discovery, pre-clinical and clinical stages of drug development.
Under GHO’s ownership the Company has experienced strong organic and inorganic growth – with revenue tripling since original investment – to become a leader in outsourced lab services for cancer immunotherapy drug trials.
A series of three bolt-on acquisitions – a laboratory from ImmuneHealth in 2016, Primity Bio in 2018 and Serametrix in 2019 – enabled the Company to expand into Europe and Asia, add additional best-in-class technical competencies and significantly grow its capacity. Caprion is now a global leader in its sector, servicing clients across its East & West Coast North American and Belgian laboratories as well as facilities in Australia.
Throughout GHO’s ownership of Caprion, significant investments were made in the operating infrastructure of the business, including but not limited to, laboratory information management systems, business development capabilities, human resources and finance functions. These measures helped to build an organisation capable of delivering consistent year on year growth, while maintaining the highest quality standards.
The Partners at GHO Capital commented:
“GHO’s partnership with Caprion’s management team represents the successful execution of a jointly developed thesis to build a transatlantic leader in the immunotherapy services market. During this period, Caprion has achieved considerable international growth, become a technological leader in its space and continued to drive industry leading service quality standards. With the investments made in recent years, Caprion is well placed to continue on its growth trajectory.”
Ropes & Gray LLP and Osler, Hoskin & Harcourt LLP acted as legal advisors to Caprion. William Blair & Company acted as financial advisor, and Kirkland & Ellis LLP and Jones Day LLP acted as legal advisors to Arsenal.
ENDS
About Caprion Biosciences
Caprion is the leading provider of specialized flow cytometry immune monitoring and quantitative mass spectrometry proteomics services to the biopharmaceutical industry. With laboratory facilities globally located in Montreal (Quebec, Canada), Fremont (California, USA), Carlsbad (California, USA), Gosselies (Belgium), Guildford (UK) and Sydney (Australia), Caprion has achieved top-tier growth in recent years both organically and through the recent acquisitions of Primity Bio and Serametrix Corporation. For more information: www.caprion.com .
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities in Europe, building market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to unlock value in a global system that demands the delivery of better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com
About Arsenal Capital Partners
Arsenal is a leading private equity firm that specializes in investments in middle-market specialty industrials and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, completed more than 40 platform investments, and achieved 30 realizations. Arsenal invests in industry sectors in which the firm has significant prior knowledge and experience and seeks companies typically in the range of $100 million to $500 million of initial enterprise value. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add. For more information, visit www.arsenalcapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190731005490/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin25.6.2025 07:00:00 CEST | Press release
Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world4-6 IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO1,3,4 Enrollment for Galderma’s phase II studies of nemolizumab is planned to begin in H2 2025 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and C
MSCI Announces Results of the MSCI 2025 Market Classification Review24.6.2025 23:55:00 CEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today the results of the MSCI 2025 Market Classification Review. Select highlights of this year’s review includes MSCI: Extending the consultation on a potential reclassification of Bulgaria from Standalone to Frontier Market status Continuing to monitor the implementation and market adoption of measures to enhance the accessibility of the Korean equity market, to determine whether these measures have replicated the outcomes of fully operational offshore FX markets such as those found in Developed Markets Providing updates on the market classification status of Greece Continuing to monitor the market accessibility of the Bangladesh equity market “MSCI is committed to ensuring that our market classifications reflect the evolving realities of global accessibility and investability,” said Raman Aylur Subramanian, Head of Index R&D. “In 2025, we have see
Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors24.6.2025 22:15:00 CEST | Press release
NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company’s 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group (“LEGO”) from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. “Jørgen’s strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent addition to our board,” said Mark Parker, Executive Chairman of NIKE, Inc. “We look forward to working with Jørgen during an exciting time for NIKE where we will unlock our next chapter of growth through innovative product and distinctive brand storytelling across an integrated marketplace.” Prior to joining L
NetApp Appoints Disruptive Innovator Syam Nair as Chief Product Officer, Underscoring its Commitment to Bold Product Vision24.6.2025 22:05:00 CEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Syam Nair as its new Chief Product Officer (CPO), effective Monday, July 7, 2025. Nair succeeds Harv Bhela, who concluded his tenure in June following a successful chapter of product leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624871234/en/ Syam Nair, Chief Product Officer at NetApp Nair is a former Salesforce and Microsoft executive renowned as a maverick innovator in the industry, bringing over 25 years of experience in scaling cloud platforms and driving hyper-growth. In his new role, Nair will lead NetApp’s product and engineering teams to accelerate innovation in hybrid cloud and AI offerings and advance NetApp’s strategic vision for data-driven business growth. “I am thrilled to welcome Syam to NetApp’s leadership team. He joins us at a time when our customers are looking to NetApp to help them deli
Mirion Technologies and Westinghouse Partner to Drive Digital Innovation in Nuclear Instrumentation Systems24.6.2025 22:04:00 CEST | Press release
Based on Mirion’s proTK™ Product Line, the Newly Designed Solution Aims to Reduce Burden and Enhance Performance in Nuclear Power Plants. Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, and Westinghouse Electric Company LLC, a leading supplier of nuclear plant instrumentation and control systems, have announced a strategic partnership to provide digital Ex-core Nuclear Instrumentation Systems (NIS) based on the high-performing Mirion proTK product line. This collaboration aims to alleviate operator and maintenance burdens, enhance performance, and ensure sustained operation success. This digital NIS upgrade solution is offered exclusively through Westinghouse for both Westinghouse and Combustion Engineering designed PWRs worldwide. This initiative leverages Mirion’s proTK product line to upgrade existing analog neutron flux monitoring drawers, which were originally designed in the 1960s, to a state-of-the-art digital system. The Mirion proTK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom